Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
PHASE2CompletedINTERVENTIONAL
Enrollment
26
Participants
Timeline
Start Date
September 4, 2015
Primary Completion Date
December 29, 2016
Study Completion Date
August 25, 2017
Conditions
Plaque Psoriasis
Interventions
DRUG
DSXS
twice daily for 28 days
Trial Locations (1)
10532
Taro Pharmaceuticals USA Inc., Hawthorne
All Listed Sponsors
lead
Sun Pharmaceutical Industries, Inc.
INDUSTRY
NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis | Biotech Hunter | Biotech Hunter